Phase IIa trial of BGB 324 in patients with chronic myeloid leukaemia
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2014
At a glance
- Drugs BGB 324 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors BerGenBio
- 23 Dec 2014 This phase IIa trial in patients with CML is being planned, according to the BerGenBio pipeline.
- 23 Dec 2014 New trial record
- 15 Dec 2014 This trial is expected to start in 2015, according to a BerGenBio media release.